Islets of Hope diabetes news headlines

islets of hope home buttondiabetes law buttonchildren with diabetes, right to educationclincal trials, research, studies buttondiabetes type 1 and type 2 support groups type 1 diabetes informationtype 2 diabetes information

diabetes news headlines and research                            Diabetes Drug R & D


Headline News and Stories Relating to Current and Future Diabetes Drug Research and Development

If you copy our list of links for your own site, we'd really appreciate it if you would add a link to our site as well.  Your support and mention of www.IsletsofHope.com will help others with diabetes.  We now donate 100% of the profits from our website to nonprofit diabetes organizations that purchase insulin, diabetes medications, and supplies for others in need.

|  Business  | Diabetes Events | Drug Research & Development   Education  | General Diabetes Studies   Human Interest  |
|  
Legislation - Diabetes, Ethics, Research  | Stem Cell Research  | Your Diabetes Health | Technology (Diabetes)  |
 FDA, UK & European Drug & Medical Updates Approvals/Rejections/Warnings
RECALLS & WARNINGS for Diabetes Medications, Products & Devices  |


November 2006

See "Current Headlines"


October 2006

Back to Top


September 2006

Back to Top


August 2006

Back to Top


July 2006

Back to Top


June 2006

  • New Study Shows Cinnamon Extract Lowers Blood Sugar Levels In People With Type 2 Diabetes - A water-soluble, cinnamonextract has been shown to reduce fasting blood sugar levels in patientswith type 2 diabetes, according to a new study from the University ofHannover in Hannover, Germany published in a recent issue of the EuropeanJournal of Clinical Investigation.  06/30/2006
  • Health Alert: Diabetes chemo - A cancer treatment is now being tested as a way to control diabetes. Testing her blood is something Kimberly Parker is still getting used to.  06/28/2006
  • Dia-B Advances Research On Anti-diabetes Compound - Melbourne biotech group Dia-B expects to begin clinical trials of its ISF402 anti-diabetes compound in the last quarter of 2006 after initial trials on animals proved that the compound is effective in lowering blood glucose levels.  06/26/2006
  • Nastech, Amylin Enter Diabetes Pact - (AP) BOTHELL, Wash. Shares of Nastech Pharmaceutical Co. gained Monday after the drug delivery technology maker announced an agreement with drug maker Amylin Pharmaceuticals Inc. to help develop a diabetes treatment in a nasal spray.  06/26/2006
  • Nastech, Amylin Enter Diabetes Pact - Shares of Nastech Pharmaceutical Co. gained Monday after the drug delivery technology maker announced an agreement with drug maker Amylin Pharmaceuticals Inc. to help develop a diabetes treatment in a nasal spray.  06/26/2006
  • Drug shows promise in blocking diabetes - The nation's 20.8 million diabetics didn't have a medication available to them to prevent the onset of the debilitating disease. But if a promising new drug being studied in San Antonio eventually gets FDA approval, 41 million pre-diabetics may be able to stave off the disease and the potentially deadly risk factors that come with it.  06/26/2006
  • Diabetes drug trial to start in 6 months - A Melbourne company is expected to begin human trials of a new oral drug to treat type 2 diabetes within six months.  Biotech group Dia-B Tech Ltd today announced it expected to begin clinical trials of its ISF402 anti-diabetes drug later this year.  06/23/2006
  • New drugs generating optimism on diabetes - Even as diabetes rates reach epidemic levels worldwide, four new drugs are generating optimism among doctors.  06/22/2006
  • Four Diabetes Drugs Raise Hope -  Doctors say the new drugs are important additions to the treatment arsenal because they work differently from existing diabetes medicines and have relatively mild side effects.  06/22/2006
  • 4 Diabetes Drugs Are Seen Raising Hope and Profit -  Even as diabetes rates reach epidemic levels worldwide, four new drugs are generating optimism among doctors as well as Wall Street analysts.  06/22/2006
  • The Molecular Mechanism Of A Diabetes Vaccine Revealed -  A team of researchers led by Prof. Irun Cohen of the Weizmann Institute of Science Immunology Department has revealed the molecular mechanism of a vaccine for Type 1 diabetes. The new findings should help amplify the effectiveness of the vaccine, which is currently in advanced stages of clinical trials.  06/22/2006
  • Molecular Mechanism Of A Diabetes Vaccine Revealed - A team of researchers led by Prof. Irun Cohen of the Weizmann Institute of Science Immunology Department has revealed the molecular mechanism of a vaccine for Type 1 diabetes. The new findings should help amplify the effectiveness of the vaccine, which is currently in advanced stages of clinical trials.  06/20/2006
  • Diabetes pills lower blood sugar, weight too - Washington - Two experimental pills seem to help older diabetes drugs lower patients' blood sugar, with the added...  06/19/2006
  • New diabetes and metabolic disorders drugs waiting in pipeline for Plexxikon - Every quarter, Plexxikon Inc. CEO Peter Hirth and his top executives sit down to do a little triage. They determine which projects will continue and which ones will be shelved.  06/19/2006
  • Positive Phase III Data for Novartis' Diabetes Drug - Novartis' investigational drug candidate Galvus, a new once-daily oral treatment option for type 2 diabetes, has demonstrated impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.  06/16/2006
  • Aliskiren superior to ramipril to control diabetes and hypertension: Novartis - Newly-released clinical data show that Rasilez (aliskiren), the first orally effective direct renin inhibitor, provided superior reductions in systolic blood pressure over the ACE inhibitor ramipril in people with diabetes and hypertension.  06/16/2006
  • Positive phase III data for Novartis' diabetes drug - Novartis investigational drug candidate Galvus, a new once-daily oral treatment option for type 2 diabetes, has demonstrated impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.  06/16/2006
  • Auxilium Pharmaceuticals Announces Top-Line Results From Phase IV Trial Of Testim(R) In Patients With Type II Diabetes - Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty pharmaceutical company,today reported top-line results from its Phase IV randomized trial ofTestim(R) 1%, its topical testosterone gel, treatment in patients with Type II diabetes.   06/16/2006
  • Mixed Results for Auxilium Drug in Diabetes Study - Auxilium Pharmaceuticals Inc., a specialty pharmaceutical company in Malvern, said today a study of its topical testosterone gel helped men with Type II diabetes lose fat and gain muscle in a clinical trial.  06/16/2006
  • Isis Diabetes Drug Improves Glucose Control in Phase II Trial - Isis Pharmaceuticals has obtained positive results from a phase II trial evaluating ISIS 113715, a novel insulin sensitizer, as a single-agent in patients with type 2 diabetes.  06/15/2006
  • New Type 2 Diabetes Drugs at FDA Stage -  Merck & Co. and Novartis AG are seeking U.S. government approval of new Type 2 diabetes drugs they claim have milder side effects than current treatments.  06/15/2006
  • Pfizer, Bayer team up to develop diabetes and obesity compounds - Pfizer Inc. received exclusive worldwide rights to a class of Bayer Pharmaceuticals Corp. compounds that could lead to treatments for diabetes and obesity, the companies said.  06/14/2006
  • New Drugs Show Promise in Controlling Diabetes - A new class of experimental drugs that aids hormones in the gut can significantly lower high blood sugar in people with type 2 diabetes without causing weight gain or other side effects, researchers said Tuesday.  06/14/2006
  • Novartis, Merck Diabetes Drugs Very Similar - New diabetes drugs from Novartis (NVS) and Merck (MRK), presented at a major medical conference, appear to be broadly similar in terms of efficacy and safety, analysts say.  06/14/2006
  • Novartis Unveils Further Impressive Efficacy Data For Galvus(R), An Investigational Oral Diabetes Compound, Showing - Galvus(R)(vildagliptin), seeking to become a new once-daily oral treatment optionfor type 2 diabetes, has demonstrated impressive efficacy, especially inpatients with poor glycemic control, as well as weight loss benefits inobese patients.  06/14/2006
  • Next diabetes drugs seem to keep the weight off - A new class of diabetes drugs can control blood sugar without causing weight gain and potentially could slow the progression of this increasingly prevalent disease, new research shows.  06/14/2006
  • 2 Diabetes Drugs May Lower Blood Sugar - Two experimental pills seem to help older diabetes drugs lower patients' blood sugar, with the added bonus of a little weight loss.  06/14/2006
  • New drugs show hope in controlling diabetes - A new class of experimental drugs that aids hormones in the gut can significantly lower high blood sugar in people with type 2 diabetes without causing weight gain or other side effects, researchers said Tuesday. Experts welcome the new therapies.  06/14/2006
  • Merck says diabetes drug on par with standard care - A diabetes drug awaiting U.S. approval helped lower blood sugar levels comparable to a conventional treatment and also helped patients lose weight, the drug's developer, Merck & Co. , said on Tuesday.  06/13/2006
  • Novo Nordisk diabetes drug highly effective: study - An experimental diabetes drug by Novo Nordisk dramatically improved blood sugar levels and lowered weight in type 2 diabetes patients in a mid-stage clinical trial, researchers said on Tuesday.  06/13/2006
  • New Diabetes Drug May Lower Blood Sugar and Weight - A new diabetes drug lowers patients' blood sugar and also helps shed some pounds.  06/13/2006
  • Merck Issues New Data on Diabetes Drug - Drug maker Merck & Co. said Tuesday that clinical data showed its Januvia diabetes treatment was not inferior to a standard treatment and significantly cut down on weight gain.  06/13/2006
  • New diabetes drugs may aid weight loss - More than 230 million people worldwide have diabetes, up from just 30 million in 1985, according to the International Diabetes Federation. Diabetes is expected to affect 350 million people by 2025.   06/13/2006
  • New diabetes drugs give double punch - Two experimental pills seem to help older diabetes drugs lower patients' blood sugar, with the added bonus of a little weight loss.  06/13/2006
  • Novartis diabetes drug effective in combo study - A Novartis AG diabetes drug currently awaiting U.S. approval significantly reduced blood sugar levels in patients with type 2 diabetes when given in combination with an older medicine called pioglitazone, researchers said on Tuesday.  06/13/2006
  • Isis Posts Diabetes Drug Study Data - Drug maker Isis Pharmaceuticals Inc. said Tuesday that its experimental diabetes treatment significantly improved measures of blood sugar control in newly diagnosed patients in a mid-stage clinical study, but blood sugar over a three-month average was not significantly improved.  06/13/2006
  • Acomplia Cuts Diabetes Patients' Risks - Acomplia, an experimental weight loss drug, helps obese people with type 2 diabetes lose weight, reduce waist size, and even control blood sugar and blood fats.  06/12/2006
  • Medical News: Coffee, Diabetes, Food Allergies - In Monday's medical news, NewsCenter 5's Heather Unruh reported on a healthy perk if you have coffee cravings, a pill that could tackle a serious side effect of diabetes, and how to make sense of your baby's food allergies.  06/12/2006
  • OSI Pharmaceuticals Reports Positive Diabetes Data - The drugmaker announced positive Phase II trial data for its lead diabetes drug candidate.  06/12/2006
  • Oramed Pharmaceuticals Combats Diabetes with Oral Insulin - Oramed Pharmaceuticals' (OTCBB: ORMP) (the 'Company') is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin   06/12/2006
  • Antidepressants may increase diabetes risk - Study findings show that there is a link between the use of antidepressant drugs and diabetes, investigators here at the 66th Scientific Sessions of the American Diabetes Association announced. This is the first report of such an association, they say.  06/12/2006
  •  Dia-B Believes Bark Could Help Diabetes Sufferers  - Melbourne based biotechnology group Dia-B Tech Limited believes that it has found a natural alternative to anti-diabetes drug insulin in the bark of a species of vine found in rainforests of the Pacific Islands. The chemical component produced from the vine occurs in traditional medicines but it has not been used for anti-diabetic or hypoglycaemic purposes.  06/12/2006
  • Antidepressants Can Increase Diabetes Risk in Certain Cases - If you are already at high risk for getting type 2 diabetes, antidepressant drugs can boost that risk, according to new research reported Saturday.  06/11/2006
  • Antidepressants may boost diabetes risk - The use of antidepressants appears to increase the onset of diabetes in some high-risk individuals, according to a government-funded study announced Saturday.  06/11/2006
  • Merck diabetes drug effective alone or as add-on - A Merck & Co. diabetes pill awaiting U.S. approval was moderately effective at reducing blood sugar levels both as a stand-alone treatment and in combination with other oral medicines in a handful of late-stage clinical trials presented Saturday.  06/10/2006
  • Easier-to-use diabetes drug passes test - Eli Lilly & Co. and Amylin, makers of the diabetes treatment Byetta, reported Saturday that a more convenient-to-use but experimental version of the drug successfully reduces blood-sugar levels.  06/10/2006
  • Merck says diabetes drug shows promise vs. hypoglycemia - In its face-off with Novartis over the multi-billion dollar diabetes market, Merck revealed a study Saturday showing that its experimental drug Januvia slashed the risk of hypoglycemia more than sixfold while matching a generic drug's ability to reduce blood-sugar level.  06/10/2006
  • Metabolex Initiates Phase 2/3 Trial of Metaglidasen in Patients With Type 2 Diabetes - Metabolex, Inc. announced today the initiation of a Phase 2/3 trial of its lead product candidate, metaglidasen, in patients with type 2 diabetes.  06/10/2006
  • Newly Released Phase III Studies for JANUVIA(TM), Merck's Investigational Once-Daily Medicine for Type 2 Diabetes, - Newly released Phase III studies presented here today at the American Diabetes Association 66th Annual Scientific Sessions demonstrated that JANUVIA , Merck and Co., Inc.'s investigational oral, once-daily medicine for type 2 diabetes, significantly reduced blood sugar levels when used as monotherapy or as an add-on treatment to two commonly used therapies.  06/10/2006
  • Merck hurries on diabetes drug - Merck & Co. said Monday that it expects to file earlier than expected for regulatory approval of an experimental combination drug for type 2 diabetes.  06/10/2006
  • Phenomix diabetes drug enters phase II - Phenomix Corporation has initiated a phase II clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes.  06/10/2006
  • Novartis, Merck Face Off Over New Diabetes Drugs - Novartis's Galvus and Merck's Januvia stand to enter the lucrative -- but highly competitive -- market of oral treatments for Type 2 diabetes. Both have been touted by analysts as potential $1 billion-a-year plus sellers.  06/09/2006
  • Incyte begins phase I diabetes study - Incyte Corporation has initiated a phase I clinical trial to evaluate the potential of INCB13739 as a new treatment for type 2 diabetes.  06/09/2006
  • Positive data for Depomed diabetes drug - A phase III trial of Depomeds Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
  • Positive Data for Depomed Diabetes Drug - A phase III trial of Depomed's Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
  • Eli Lilly and Alkermes Progressing With Diabetes Safety Study - Eli Lilly and Alkermes have completed patient enrollment in a pivotal safety study required for registration for their AIR inhaled insulin system, which is being investigated as an innovative treatment option for diabetes.  06/07/2006
  •  DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
  • DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
  •  Merck Hurries on Diabetes Drug - Merck & Co. said Monday it expects to file earlier than expected for regulatory approval of an experimental combination drug for type 2 diabetes.  06/07/2006
  • Phenomix diabetes drug enters phase II - Phenomix Corporation has initiated a phase II clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes.  06/10/2006
  • Novartis, Merck Face Off Over New Diabetes Drugs - Novartis's Galvus and Merck's Januvia stand to enter the lucrative -- but highly competitive -- market of oral treatments for Type 2 diabetes. Both have been touted by analysts as potential $1 billion-a-year plus sellers.  06/09/2006
  • Incyte begins phase I diabetes study - Incyte Corporation has initiated a phase I clinical trial to evaluate the potential of INCB13739 as a new treatment for type 2 diabetes.  06/09/2006
  • Positive data for Depomed diabetes drug - A phase III trial of Depomeds Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
  • Positive Data for Depomed Diabetes Drug - A phase III trial of Depomed's Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
  • Eli Lilly and Alkermes Progressing With Diabetes Safety Study - Eli Lilly and Alkermes have completed patient enrollment in a pivotal safety study required for registration for their AIR inhaled insulin system, which is being investigated as an innovative treatment option for diabetes.  06/07/2006
  • DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
  • DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
  •  Merck Hurries on Diabetes Drug - Merck & Co. said Monday it expects to file earlier than expected for regulatory approval of an experimental combination drug for type 2 diabetes.  06/07/2006
  • Clinical trials will determine if diabetes drug helps hearts - Groundbreaking clinical trials are under way at Allegheny General Hospital to determine if a drug currently being used to treat diabetes could also be effective in repairing a damaged heart.  06/05/2006
  • Dumaguing: Actos a logical diabetes drug of choice - Breakfast sessions in medical conferences, whether local or international, are usually not very popular. For one, it starts at 7:30 a.m. when most of the doctors are still curled up in bed, understandably catching up with sleep, which is luxury item if they are in their place of practice.  06/04/2006
  • Clinical trials will determine if diabetes drug helps hearts - Groundbreaking clinical trials are under way at Allegheny General Hospital to determine if a drug currently being used to treat diabetes could also be effective in repairing a damaged heart.  06/05/2006
  • Dumaguing: Actos a logical diabetes drug of choice - Breakfast sessions in medical conferences, whether local or international, are usually not very popular. For one, it starts at 7:30 a.m. when most of the doctors are still curled up in bed, understandably catching up with sleep, which is luxury item if they are in their place of practice.  06/04/2006
  • Increased sensitivity to nerve signals keeps diabetes at bay - Nerve signals relayed directly to the pancreas after eating a meal play a critical role in normal blood sugar control, according to a report in the June 7, 2006, Cell Metabolism. Therefore, drugs that increase the sensitivity to such signals might offer a new approach to diabetes treatment, the researchers said. 06/06/2006
  • (AFX UK Focus) 2006-06-05 14:58 GMT: Merck to file Januvia diabetes type II drug in 2006; earlier than expected - Merck & Co Inc said it expects to file a new drug application for its type 2 diabetes drug Januvia to the Food and Drug Administration in 2006, earlier than its initially anticipated 2007 date.  06/05/2006
  • Researchers Pinpoint Causes Of Adverse Reactions To Popular Type 2 Diabetes Drugs - Used by several million people worldwide, rosiglitazone (RSG) is an oral agent that helps patients with type 2 diabetes to maintain good blood glucose levels by improving how their bodies use insulin.  06/02/2006
  • Drug for Type 2 Diabetes helps with weight loss.  - Research shows that a new drug for Type 2 Diabetes has an interesting side effect, weight loss. That's great news for diabetics, and now some are wondering if it might help people who don't have diabetes lose weight too.  06/01/2006

Back to Top


May 2006

Back to Top


April 2006

Back to Top


March 2006

Back to Top


February 2006

Back to Top


January 2006

Back to Top


December 2005

Back to Top


November 2005

Back to Top


October 2005

Back to Top


September 2005

Exubera approved by FDA). Exubera. an inhaled insulin, won endorsement today from an FDA despite concerns about the agent's pulmonary toxicity. 09/08/05

Back to Top


August 2005

Back to Top


July 2005

Novo Nordisk Launches GlucaGen® HypoKit™  07/05/05

Back to Top


Diabetes Headline News Resources

 

Contact Us  |  About IOH  |  Our Mission  |  Elizabeth's Story  |  About the Founder  |  Join IOH  |  How To Help  |  Advertise  |  Privacy Statement |  Site Index  |

Page Updated 11/01/2006